Cara Therapeutics to Discontinue Clinical Program to Treat Notalgia Paresthetica Disease

Dow Jones06-13

By Sabela Ojea

Cara Therapeutics said it is discounting a clinical program to treat patients with notalgia paresthetica on the outcome from the dose-finding part A of its Kourage-1 study.

The commercial-stage biopharmaceutical company on Wednesday said it is disappointed that oral difelikefalin failed to demonstrate a meaningful clinical benefit at any dose compared to placebo during the study.

Notalgia paresthetica is a chronic condition that causes a localized itch in the upper back.

"We will be winding down the Phase 2/3 clinical program in notalgia paresthetica and exploring strategic alternatives focused on maximizing shareholder value," Chief Executive Christopher Posner said.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

June 12, 2024 16:24 ET (20:24 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2443594452?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-13 04:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2443594452","market":"hk","top_or_hot":-1,"title":"Cara Therapeutics to Discontinue Clinical Program to Treat Notalgia Paresthetica Disease","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Cara <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said it is discounting a clinical program to treat patients with notalgia paresthetica on the outcome from the dose-finding part A of its Kourage-1 study. \n</p>\n<p>\n  The commercial-stage biopharmaceutical company on Wednesday said it is  disappointed that oral difelikefalin failed to demonstrate a meaningful clinical benefit at any dose compared to placebo during the study. \n</p>\n<p>\n  Notalgia paresthetica is a chronic condition that causes a localized itch in the upper back. \n</p>\n<p>\n  \"We will be winding down the Phase 2/3 clinical program in notalgia paresthetica and exploring strategic alternatives focused on maximizing shareholder value,\" Chief Executive Christopher Posner said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 12, 2024 16:24 ET (20:24 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cara Therapeutics to Discontinue Clinical Program to Treat Notalgia Paresthetica Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCara Therapeutics to Discontinue Clinical Program to Treat Notalgia Paresthetica Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-13 04:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Sabela Ojea \n\n\n \n\n\n  Cara Therapeutics said it is discounting a clinical program to treat patients with notalgia paresthetica on the outcome from the dose-finding part A of its Kourage-1 study. \n\n\n...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2443594452","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2443594452","pubTimestamp":1718223840,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Cara Therapeutics said it is discounting a clinical program to treat patients with notalgia paresthetica on the outcome from the dose-finding part A of its Kourage-1 study.The commercial-stage biopharmaceutical company on Wednesday said it is  disappointed that oral difelikefalin failed to demonstrate a meaningful clinical benefit at any dose compared to placebo during the study.Notalgia paresthetica is a chronic condition that causes a localized itch in the upper back.\"We will be winding down the Phase 2/3 clinical program in notalgia paresthetica and exploring strategic alternatives focused on maximizing shareholder value,\" Chief Executive Christopher Posner said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CARA":"Cara Therapeutics, Inc."},"translate_title":"Cara Therapeutics将停止治疗感觉异常性疼痛的临床项目","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CARA":1},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Cara Therapeutics said it is discounting a clinical program to treat patients with notalgia paresthetica on the outcome from the dose-finding part A of its Kourage-1 study. \n\n\n  The commercial-stage biopharmaceutical company on Wednesday said it is  disappointed that oral difelikefalin failed to demonstrate a meaningful clinical benefit at any dose compared to placebo during the study. \n\n\n  Notalgia paresthetica is a chronic condition that causes a localized itch in the upper back. \n\n\n  \"We will be winding down the Phase 2/3 clinical program in notalgia paresthetica and exploring strategic alternatives focused on maximizing shareholder value,\" Chief Executive Christopher Posner said. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 12, 2024 16:24 ET (20:24 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2443594452"}